Navigation Links
Peregrine Pharmaceuticals to Report Second Quarter FY 2009 Financial Results
Date:12/4/2008

TUSTIN, Calif., Dec. 4/PRNewswire-FirstCall/ --Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today announced that it will release its financial results for the second quarter of fiscal year 2009 on December 10, 2008 at 7:00 a.m. EST and will host a conference call and webcast to discuss the results at 11:30 a.m. EST on the same day.

Peregrine's senior management will discuss financial results for the second quarter ended October 31, 2008 and will review recent operating highlights. A question-and-answer session will follow management's discussion. All interested parties are encouraged to listen to the live conference call or the archived webcast.

The conference call and webcast will begin at 11:30 a.m. EST/ 8:30 a.m. PST.

To listen to a live broadcast of the call over the Internet or to review the archived webcast, please visit: http://www.peregrineinc.com. The webcast will be archived on Peregrine's website for 30 days.

To listen to the conference call via telephone, please call the following number approximately 10 minutes prior to the scheduled start time and request to join the Peregrine Pharmaceuticals call: (800) 860-2442. A telephonic replay of the conference call will be available starting approximately one hour after the conclusion of the call through December 17, 2008 by calling (877) 344-7529, passcode 382933#.

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative product candidates in clinical trials for the treatment of cancer and hepatitis C virus (HCV) infection. The company is pursuing three separate clinical programs in cancer and HCV infection with its lead product candidates bavituximab and Cotara(R). Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and bio-manufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at www.peregrineinc.com.

    Contacts:
    GendeLLindheim BioCom Partners
    Investors
    info@peregrineinc.com
    (800) 987-8256

    Media
    Barbara Lindheim
    (212) 918-4650


'/>"/>
SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Peregrine Pharmaceuticals to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
2. Peregrine Pharmaceuticals to Present at BIO Investor Forum 2008
3. Peregrine Pharmaceuticals Receives Additional Time to Regain Compliance With NASDAQs Minimum Bid Price Rule
4. Peregrine Pharmaceuticals Reports Progress in Its Phase II Trial of Bavituximab Plus Docetaxel in Patients With Advanced Breast Cancer
5. Peregrine Pharmaceuticals Completes Patient Enrollment In First Stage of Bavituximab Phase II Lung Cancer Trial
6. Peregrine Pharmaceuticals Reports Financial Results for the First Quarter of Fiscal Year 2009
7. Peregrine Pharmaceuticals to Report First Quarter FY 2009 Financial Results
8. Peregrine Pharmaceuticals Receives Letter from NASDAQ Citing Failure to Regain Compliance with Minimum Bid Price Rule
9. Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2008
10. Peregrine Pharmaceuticals Awarded DTRA Contract Worth up to $44.4 Million to Develop Bavituximab for Viral Hemorrhagic Fevers
11. Peregrine Pharmaceuticals Presents Promising Phase I Data at ASCO and Provides Clinical Update on Its Phase II Bavituximab Breast Cancer Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2017)... ... June 23, 2017 , ... ... of a redesigned, easier-to-navigate website for all six of their healthcare job ... nurses, dentists, pharmacists, physical and occupational therapists, and biotechnicians, DocCafe.com and the ...
(Date:6/22/2017)... ... June 21, 2017 , ... Building on the success of the inaugural ... on the very latest developments in radical life extension. RAADfest combines cutting edge science ... the empowerment of personal development, making it the largest most comprehensive and inclusive super ...
(Date:6/22/2017)... , ... June 22, 2017 , ... ... results to clients throughout the biopharma and life sciences industries, continue to be ... is seeing. Tunnell’s Kip Wolf will be speaking on “The State of Information ...
(Date:6/20/2017)... ... 20, 2017 , ... CTNext , Connecticut’s go-to resource ... a Higher Education Entrepreneurship Advisory Committee to implement the recommendations of the master ... representatives from 35 higher education institutions across the state over the past six ...
Breaking Biology Technology:
(Date:4/13/2017)... , April 13, 2017 UBM,s Advanced ... will feature emerging and evolving technology through ... Innovation Summits will run alongside the expo portion of ... sessions, panels and demonstrations focused on trending topics within ... advanced design and manufacturing event will take place June ...
(Date:4/11/2017)... Florida , April 11, 2017 ... a security technology company, announces the appointment of independent Directors ... Bendheim to its Board of Directors, furthering the company,s ... ... of NXT-ID, we look forward to their guidance and benefiting ...
(Date:4/4/2017)... 4, 2017   EyeLock LLC , a leader ... United States Patent and Trademark Office (USPTO) has issued ... linking of an iris image with a face image ... the company,s 45 th issued patent. ... timely given the multi-modal biometric capabilities that have recently ...
Breaking Biology News(10 mins):